Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US-2022184185-A1 · Jun 16, 2022 · US
This page is not indexed by search engines while we improve data quality.
Mendlein John patents
Mendlein John is listed as an inventor on 7 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Mendlein John |
| Total patents | 7 |
| First publication | Sep 10, 2015 |
| Latest publication | Jun 16, 2022 |
Notable patents
Publications ranked by popularity score, then publication date.
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US-11149077-B2 · Oct 19, 2021 · US
Hematopoietic stem and progenitor cell therapy
US-2020339953-A1 · Oct 29, 2020 · US
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US-2019202894-A1 · Jul 4, 2019 · US
Methods of treating cancer by administering IGF-IR binding molecules
US-10221232-B2 · Mar 5, 2019 · US
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US-2017190761-A1 · Jul 6, 2017 · US
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US-2015252097-A1 · Sep 10, 2015 · US
Recent patents
Latest publications not already listed above.
No data yet.
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Bristol Myers Squibb Co | 5 |
| Fate Therapeutics Inc | 1 |
| Modernatx Inc | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P43/00 | 6 |
| A61P35/00 | 6 |
| C40B40/10 | 5 |
| C07K2317/92 | 5 |
| A61K47/60 | 5 |